Search

The article presents a case study of Cytokinetics Inc., which has worked with the pharmaceutical chemical manufacturer, Irix Pharmaceuticals Inc., to develop a synthetic small-molecule drugs to treat diseases. It states that Irix has used the medicinal chemistry process in manufacturing ispinesib, and create new approach of introducing ispinesib's chiral center with a D-amino acid. It mentions that Irix was awarded the patent for using amino acid to introduce chirality into an ispinesib.

Discusses the growth of the biopharmaceutical contract manufacturing industry. Pharmaceutical companies' partnership with third parties to develop drugs; Lonza Biologics' development of Zovant, a drug to treat sepsis, for Eli Lilly and Co.; Lonza's development and manufacturing contracts with other companies; Boehringer Ingelheim's expansion of its contract manufacturing business. INSET: Biopharma technologies converge downstream..

The article presents a case study regarding the collaboration between U.S.-based biopharmaceutical start-up firm Ilypsa Inc. and German custom manufacturer Saltigo to develop polymeric pharmaceutical products. The partnership with Saltigo allows Ilypsa to take advantage of the other firm's skills in the field of multi-step chemical synthesis. According to German polymer chemist and Ilypsa's chief business officer Gerrit Klaerner, they wanted to provide solutions to life-threatening diseases.

Focuses on the focus of chemical company exhibitors at the Informex custom manufacturing trade show in Las Vegas, Nevada on new kilogram-scale facilities for small quantities of drug compounds made under current Good Manufacturing Practice standards. Question whether the overcapacity plaguing the large-volume end of the custom manufacturing business will migrate to the small-scale end; Reference to companies that are poised to expand its operations; Extension of the Informex theme of kiloscale manufacturing into the nonpharmaceutical realm.

The article reports on advancements in the developmental opioid NKTR-181 by biotechnology company Nektar Therapeutics. Topics include the public health goal of the company's new drug development, Phase III clinical trial on long-term safety of NKTR-181, and comments from Nektar chief scientific officer Stephen K. Doberstein.

The article reports on the alliance between drugmaker Ramsey Lake Pharma and pharmaceutical chemistry firm Dalton Pharma Services as of April 2016 that led to the development of cancer drug VR23. Topics include the firms' push for the cancer drug candidate closer to market, the need to carry out a systematic toxicology study that would pass regulatory muster, and the plan to start clinical trials by 2018.

The article offers information on the funds that will be given by Bill & Melinda Gates Foundation to Novartis for the development of drug KDU731 that is used to treat cryptosporidiosis that causes child mortality.

The article reports the production and development of reteplase which is one of the primary ingredients in a drug called Retavase by Wacker Biotech for Italian drug company Chiesi.

The article informs that Celgene has announced to offers additional funding into Forma Therapeutics to expand their small molecule drug discovery partnership to include targeting of protein homeostasis, inflammation, immunology, and neurodegeneration.

The article informs that Vertex Pharmaceuticals will pay X-Chem an undisclosed up-front payment as part of a small-molecule drug discovery pact targeting severe, genetic diseases.

The article discusses the case of Anacor Pharmaceuticals which is developing a family of boron-containing small-molecule drugs. It cites that the company is being assisted by contract research company Naeja Pharmaceuticals and has licensed one of the molecules to GlaxoSmithKline. It details the identification of the target of the compound AN2690 called LeuRS. It mentions that Anacor launched Phase III clinical trials for AN2690 in December 2010.

The article reports on the annual ChemOutsouring conference held in Long Branch, New Jersey in September 2010. Participants were encouraged by speakers from firms like Pfizer, Merck & Co., and Abbott Laboratories to hire third parties to hold many of the chemistry components of drug discovery and development. The contract research organizations (CROs) were commended by panelists for their services. Many executives see opportunities for growth amid downsizing and restructuring at big companies.

The article reports on the re-launch of contract research firm BioDuro, which will offers end-to-end drug discovery and development services, and also mentions the views of Chief Executive Officer Cyrus K. Mirsaidi on the same.

The article reports on efforts of pharmaceutical firm AstraZeneca to incorporate genomics into drug discovery and development; and mentions plans to work with Institute for Molecular Medicine to study genes of interest in the Finnish population.

The article reports on the expansion of the drug product development capacity of Aesica Pharmaceuticals in England.

The article focuses on the partnership between Adherex Technologies Inc. and Scynexis Inc. Lacking an in-house chemistry capabilities, Adherex has not able to develop a follow-on to its lead drug candidate, ADH-1. Because of Scynexis' chemistry skills, Adherex signed a deal with the company that allowed it to tackle small-molecule N-cadherin antagonists in earnest.

The article discusses the reason why DSM signed an outsourcing contract with Rigel Pharmaceuticals Inc. In November 2004, Rigel has discovered a small-molecule oncology drug, which they named R763. Furthermore, because of the capability of DSM to mass produce the drug and because of the strength of its enzyme expertise, the company became one of the potential outsourcing partners of Rigel.

Focuses on Ricerca Biosciences' provision of both biology and chemistry services to virtual pharmaceutical company Concordia Pharmaceuticals in order to develop the anticancer compound farnesylthiosalicylic acid. Ricerca's responsibilities in Investigational New Drug filing with the U.S. Food and Drug Administration; Biology role during clinical trials of the anticancer drug.

Discusses the evolution of combinatorial chemistry. Role of combinatorial chemistry in drug discovery; High-throughput screening of combinatorial chemistry libraries to find drug candidates; Evolution of combinatorial techniques at companies that supply compound libraries to other firms.

The article reports that the life science firm Sigma-Aldrich Corp. will fund researches of six professors at the Scripps Research Institute including Phil S. Baran, Benjamin F. Cravatt and Philip Dawson and they will provide useful molecular building blocks related to drug discovery.

The article presents profiles for several startup chemical companies, including AgriMetis, DiCE Molecules and Inpria. Topics discussed include the intention of AgriMetis to invest in the development of crop protection chemicals, DiCE Molecules' use of the DNA-directed iterative process developed by biochemistry professor Pehr Harbury for drug discovery and the use of inorganic chemistry by Inpria to develop a photoresist for extreme ultraviolet lithography.

The article reports on the findings of the study conducted by Cleveland Clinic researchers regarding the ability of the drug torcetrapib from Pfizer Inc. to slow down plaque buildup in the coronary arteries. It was found that the drug does not slow arterial plaque buildup despite increasing the levels of high-density lipoprotein cholesterol by 60 percent. Pfizer already ceased the development of the drug after the safety board revealed that the drug increased the risk of patient death.

Reports on Merck & Co. Inc.'s collaboration with Vertex Pharmaceuticals Inc. to develop a small-molecule cancer drug, an Aurora kinase inhibitor expected to enter phase I clinical development in 2004. Role of Aurora kinases in the development and progression of cancer; Merck's funding of Vertex under the agreement.

Discusses efforts by Microbia Inc.'s Precision Engineering unit raise money to fund a drug discovery in the United States. Rounds of venture-capital investment; List of drugs in development at Microbia; Appointment of medicinal chemist John J. Talley as vice president of drug discovery.

Reports on five California research institutions' formation of a consortium called BioPharmaceutical Support for Translating and Advancing Research and Technology (PharmaSTART). Goal of moving potential drugs out of the state's laboratories and into the pharmaceutical industry; Leadership of PharmaSTART by SRI International; Forms of assistance to be given to drug developers.

Focuses on the use of oligonucleotides in drug development by pharmaceutical companies in the U.S. Development of Macugen for the treatment of a disease causing blindness by Pfizer; Commercialization of Aventis' Genta for cancer; Production of nucleotide active ingredients for drug manufacturers.

Focuses on the efforts of pharmaceutical industry to discover more drugs in the U.S. Highlights of the 'Drug Discovery Technology' conference; Improvement on the productivity in drug development; Details on chemogenomic tool from Spotfire for scientific data management system.